PHARM 2 Exam 1 Questions & Answers 2026/2027 | 54 Questions | CNS, ANS, Neurotransmitters, Adrenergic Receptors, Drug Development & Pain

This comprehensive PHARM 2 Exam 1 2026/2027 study guide contains 54 questions and answers across 9 pages and is presented as an Already Graded A+ exam-preparation resource. It covers the central and peripheral nervous systems, autonomic and somatic nervous systems, neuronal transmission, neurotransmitters, sympathetic and parasympathetic responses, cholinergic and adrenergic receptors, pharmacologic agonists and antagonists, drug development and regulation, and nociceptive versus neuropathic pain. The cover on page 1 clearly identifies the material as PHARM 2 Exam 1 for 2026/2027, while the opening questions establish the neurological foundations needed for understanding autonomic pharmacology. The first section reviews the organization and physiology of the nervous system. Students distinguish the CNS as the brain and spinal cord from the peripheral nervous system involving cranial and spinal nerves. The document further separates the autonomic nervous system (ANS) into sympathetic and parasympathetic divisions and associates the somatic nervous system with skeletal muscle. Afferent sensory and efferent motor pathways are introduced alongside neuronal action potentials, protein enzymes, receptor-binding capacity, hypoxia, acidosis and alkalosis as factors affecting neuronal transmission. A major portion concentrates on neurotransmitters and autonomic nervous system pharmacology. The material reviews serotonin, dopamine, acetylcholine, norepinephrine and GABA and explains terminology such as serotonergic, dopaminergic, cholinergic, noradrenergic and GABAergic. Students compare the sympathetic “fight or flight” response with the parasympathetic “rest and digest” response, including their effects on heart rate, blood pressure, blood flow, glucose availability, digestion, pupils, bladder function and bronchial tone. The study guide also identifies acetylcholine as central to parasympathetic signaling and norepinephrine as an important sympathetic neurotransmitter. The receptor section provides concentrated review of cholinergic and adrenergic receptor subtypes. Cholinergic receptors are divided into nicotinic N, nicotinic M and muscarinic receptors, with the material connecting them to autonomic ganglia, skeletal-muscle contraction, parasympathetic organ responses and sympathetic sweat glands. Adrenergic content includes alpha-1, alpha-2, beta-1 and beta-2 receptors. The questions associate alpha-1 activation with vasoconstriction and increased blood pressure, beta-1 with increased cardiac rate, conduction, contractility and renin release, and beta-2 with bronchodilation, vasodilation, glycogenolysis and uterine relaxation. Students also review the pharmacologic concepts of agonists and antagonists and how drugs influence synaptic transmission. An agonist is described as binding to a receptor and activating it, with morphine given as an example, whereas an antagonist binds and blocks activation, illustrated by naloxone blocking morphine. The material emphasizes synaptic transmission and axonal conduction and reviews drug effects involving neurotransmitter synthesis, storage, release, transmission and receptor binding. The guide then transitions to drug regulation and clinical drug development. It covers the 1962 Harris-Kefauver Amendment and the 1970 Controlled Substances Act as presented in the course material. Drug development is organized into preclinical testing followed by Phase I, Phase II, Phase III and Phase IV, progressing from nonhuman toxicity and safety testing through increasingly larger human populations and eventual use in the general public. These questions provide a concise framework for understanding the regulatory and experimental pathway associated with medication development. The final section focuses extensively on pain physiology and classification. Students distinguish nociceptive pain associated with tissue injury from non-nociceptive or neuropathic pain associated with nervous-system dysfunction. Nociceptive pain is further divided into somatic and visceral pain, while the guide reviews A-delta fibers, C fibers and referred pain. A-delta fibers are associated with sharp, localized pain, whereas C fibers are associated with dull, aching, throbbing and less-localized pain. Visceral pain originates from internal organs and their linings and is characterized as poorly localized in the document. Neuropathic pain receives additional attention through descriptions such as burning, shooting, shock-like and tingling sensations. The document differentiates central neuropathic pain caused by CNS damage from peripheral neuropathic pain caused by nerve damage and reviews hyperalgesia, allodynia, pain threshold and pain tolerance using the definitions supplied in the study guide. The final question introduces abstinence syndrome/withdrawal, completing an exam resource that connects foundational neurophysiology with pharmacologic mechanisms and pain management concepts. Relevant students: This document is especially relevant to Pharmacology II students, nursing students, BSN students, RN students, nurse practitioner students, allied-health students, pharmacy and pharmacology learners, and healthcare students preparing for an Exam 1 covering autonomic pharmacology, neurotransmission, receptor pharmacology, drug development and pain physiology. The uploaded source identifies the course only as PHARM 2 and does not state a university, so University Not Specified is used rather than assigning an unsupported institution. Keywords: PHARM 2 Exam 1, Pharmacology 2 Exam 1, PHARM 2 questions and answers, PHARM , pharmacology exam questions, pharmacology study guide, CNS pharmacology, central nervous system, peripheral nervous system, autonomic nervous system, ANS pharmacology, somatic nervous system, afferent nerves, efferent nerves, synaptic transmission, neurotransmitters, serotonin, dopamine, acetylcholine, norepinephrine, GABA, sympathetic nervous system, parasympathetic nervous system, fight or flight, rest and digest, cholinergic receptors, nicotinic receptors, muscarinic receptors, adrenergic receptors, alpha 1 receptor, alpha 2 receptor, beta 1 receptor, beta 2 receptor, agonist antagonist pharmacology, drug receptors, drug development phases, Harris Kefauver Amendment, Controlled Substances Act, nociceptive pain, neuropathic pain, somatic pain, visceral pain, referred pain, A delta fibers, C fibers, hyperalgesia, allodynia, pain threshold, pain tolerance, abstinence syndrome, nursing pharmacology exam